Inhaled vaccine delivery could take on not only COVID-19, but also other respiratory infections, including tuberculosis.
An inhaled COVID-19 vaccine would go directly to where the body would use it: the mucosal surface of the airways. This could mean less waste and more benefit, lower costs and reduced side-effects.
A new network of public clinical trials institutes is urgently needed to replenish the empty pipeline for new antibiotics.
Various strategies are being pursued to boost worldwide vaccine coverage.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
Konstantin Nechaev / Alamy Stock Photo
The R21 vaccine protected three-quarters of children against malaria in trials.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
Universities are the unsung heroes of vaccine development.
Cultura Creative RF / Alamy Stock Photo
The development of the COVID-19 vaccines is part of a vast system of public subsidies and universities, not corporate ambition.
Wouldn’t it be nice if one shot could protect you for life?
Bryan R. Smith/AFP via Getty Images
You need a new shot every year because current flu vaccines provide limited and temporary protection. But researchers’ new strategy could mean a one-and-done influenza vaccine is on the way.
Mahesh Kumar A/AP
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
University of Oxford
What normally takes decades has been achieved in 12 months, without cutting corners.
On Dec. 8, 2020, the first members of the public were given doses of a coronavirus vaccine.
AP Photo/Frank Augstein, Pool
The coronavirus vaccine was developed faster than any vaccine in history. It took just 332 days from the first sequencing of the virus genome to the first vaccines given to the public.
The pharmaceutical industry opposes the suspension of intellectual property rights on COVID-19 vaccines and treatments, and no pharma companies have yet contributed to the COVID-19 Technology Access Pool.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Mink can be readily infected with SARS-CoV-2 and then pass the virus to humans.
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Any COVID-19 vaccine is likely to be given first to higher risk groups before it is given to children. But we still need vaccines that are safe and effective for them too.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they’re being tested and manufactured, and what challenges there will be to rolling them out.
Hagen Hopkins/Getty Images
New Zealand has entered several international agreements to access COVID-19 vaccines, but it should also amend domestic patent law and regulatory processes to prevent delays and costly negotiations.
Samples from volunteers are handled in the laboratory at Imperial College in London, on July 30, 2020. Imperial College is working on the development of a COVID-19 vaccine.
(AP Photo/Kirsty Wigglesworth)
With lives depending on a vaccine, trust in Canada’s COVID-19 Vaccine Task Force is crucial. Members of the task force need to make any industry links or potential conflicts of interest publicly clear.